2cureX announces changes to the Board of Directors.
2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance resulting in four Board members leaving the Board of Directors.
The company is transitioning from a centralized model, where drug sensitivity testing is solely conducted in its Copenhagen laboratories, to a decentralized business model. This shift will enable IndiTreat testing at various hospitals throughout Europe and beyond.
Tonni Bülow-Nielsen, Chairman of the Board, explains, “This strategic evolution requires an adaptation in our Board of Directors and Management, introducing new expertise, connections, and insights that align with our evolving business approach.” He adds, “consequently, four Board members have chosen to depart. We are currently engaging with highly qualified individuals possessing extensive knowledge in Diagnostics and Medtech, aiming to significantly strengthen our Board in the near future.”
The exiting members, Povl-Andre’ Bendz, Camilla Huse Bondesson, Michael Schaeffer, and Michel Klimkeit, are concluding their lengthy service on the Board. Vice-Chairman and Founder Ole Thastrup expresses “deep appreciation for their contributions to 2cureX's development”.